Memorial Sloan Kettering Cancer Center

New York, NY

Sorting 19 by

Accepting patients

Optimized Cord Blood Transplant

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
  • Cord Blood
  • Phase 2

Accepting patients

Cord Blood Transplant

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults
  • Cord Blood
  • Phase 2

Accepting patients

Cord Blood Transplantation in Children

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

RALLY-MF

RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
  • Monoclonal Antibody
  • Hemojuvelin (HJV)
  • Randomization
  • Monotherapy
  • Phase 1/2
  • Has results

Not currently accepting

REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
  • MYB mRNA Degrader
  • Phase 1

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

Orca-Q

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

ACCELERATE

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Post-Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Cirtuvivint

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
  • Dual Specificity TK Inhibitor (DYRK)
  • CLK Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1